Cargando…

Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma

With 15 drugs currently approved for the treatment of metastatic renal cell carcinoma (mRCC) and even more combination regimens with immunotherapy on the horizon, there remains a distinct lack of molecular biomarkers for therapeutic efficacy. Our study reports on real-world clinical outcomes of mRCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Viola J., Hernandez-Meza, Gabriela, Agrawal, Prashasti, Zhang, Chiyuan A., Xie, Lijia, Gong, Cynthia L., Hoerner, Christian R., Srinivas, Sandy, Oermann, Eric K., Fan, Alice C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678132/
https://www.ncbi.nlm.nih.gov/pubmed/31319594
http://dx.doi.org/10.3390/cancers11071000
_version_ 1783441028077846528
author Chen, Viola J.
Hernandez-Meza, Gabriela
Agrawal, Prashasti
Zhang, Chiyuan A.
Xie, Lijia
Gong, Cynthia L.
Hoerner, Christian R.
Srinivas, Sandy
Oermann, Eric K.
Fan, Alice C.
author_facet Chen, Viola J.
Hernandez-Meza, Gabriela
Agrawal, Prashasti
Zhang, Chiyuan A.
Xie, Lijia
Gong, Cynthia L.
Hoerner, Christian R.
Srinivas, Sandy
Oermann, Eric K.
Fan, Alice C.
author_sort Chen, Viola J.
collection PubMed
description With 15 drugs currently approved for the treatment of metastatic renal cell carcinoma (mRCC) and even more combination regimens with immunotherapy on the horizon, there remains a distinct lack of molecular biomarkers for therapeutic efficacy. Our study reports on real-world clinical outcomes of mRCC patients from a tertiary academic medical center treated with empirically selected standard-of-care therapy. We utilized the Stanford Renal Cell Carcinoma Database (RCCD) to report on various outcome measures, including overall survival (OS) and the median number of lines of targeted therapies received from the time of metastatic diagnosis. We found that most metastatic patients did not survive long enough to attempt even half of the available targeted therapies. We also noted that patients who failed to receive a clinical benefit within the first two lines of therapy could still go on to experience clinical benefit in later lines of therapy. The term, “clinical benefit” was assigned to a line of therapy if a patient remained on drug treatment for three months or longer. Moreover, patients with clinical benefit in at least one line of therapy experienced significantly longer OS compared to those who did not have clinical benefit in at least one line of therapy. Developing biomarkers that identify patients who will receive clinical benefit in individual lines of therapy is one potential strategy for achieving rational drug sequencing in mRCC.
format Online
Article
Text
id pubmed-6678132
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66781322019-08-19 Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma Chen, Viola J. Hernandez-Meza, Gabriela Agrawal, Prashasti Zhang, Chiyuan A. Xie, Lijia Gong, Cynthia L. Hoerner, Christian R. Srinivas, Sandy Oermann, Eric K. Fan, Alice C. Cancers (Basel) Article With 15 drugs currently approved for the treatment of metastatic renal cell carcinoma (mRCC) and even more combination regimens with immunotherapy on the horizon, there remains a distinct lack of molecular biomarkers for therapeutic efficacy. Our study reports on real-world clinical outcomes of mRCC patients from a tertiary academic medical center treated with empirically selected standard-of-care therapy. We utilized the Stanford Renal Cell Carcinoma Database (RCCD) to report on various outcome measures, including overall survival (OS) and the median number of lines of targeted therapies received from the time of metastatic diagnosis. We found that most metastatic patients did not survive long enough to attempt even half of the available targeted therapies. We also noted that patients who failed to receive a clinical benefit within the first two lines of therapy could still go on to experience clinical benefit in later lines of therapy. The term, “clinical benefit” was assigned to a line of therapy if a patient remained on drug treatment for three months or longer. Moreover, patients with clinical benefit in at least one line of therapy experienced significantly longer OS compared to those who did not have clinical benefit in at least one line of therapy. Developing biomarkers that identify patients who will receive clinical benefit in individual lines of therapy is one potential strategy for achieving rational drug sequencing in mRCC. MDPI 2019-07-17 /pmc/articles/PMC6678132/ /pubmed/31319594 http://dx.doi.org/10.3390/cancers11071000 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Viola J.
Hernandez-Meza, Gabriela
Agrawal, Prashasti
Zhang, Chiyuan A.
Xie, Lijia
Gong, Cynthia L.
Hoerner, Christian R.
Srinivas, Sandy
Oermann, Eric K.
Fan, Alice C.
Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma
title Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma
title_full Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma
title_fullStr Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma
title_full_unstemmed Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma
title_short Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma
title_sort time on therapy for at least three months correlates with overall survival in metastatic renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678132/
https://www.ncbi.nlm.nih.gov/pubmed/31319594
http://dx.doi.org/10.3390/cancers11071000
work_keys_str_mv AT chenviolaj timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma
AT hernandezmezagabriela timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma
AT agrawalprashasti timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma
AT zhangchiyuana timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma
AT xielijia timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma
AT gongcynthial timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma
AT hoernerchristianr timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma
AT srinivassandy timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma
AT oermannerick timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma
AT fanalicec timeontherapyforatleastthreemonthscorrelateswithoverallsurvivalinmetastaticrenalcellcarcinoma